首页> 美国卫生研究院文献>Scientia Pharmaceutica >Floating Matrix Dosage Form for Propranolol Hydrochloride Based on Gas Formation Technique: Development and In Vitro Evaluation
【2h】

Floating Matrix Dosage Form for Propranolol Hydrochloride Based on Gas Formation Technique: Development and In Vitro Evaluation

机译:基于气体形成技术的盐酸普萘洛尔浮基质剂型的研制与体外评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Gastroretentive tablets of propranolol hydrochloride were developed by direct compression method using citric acid and sodium bicarbonate as the effervescent base. Hydroxypropyl methylcellulose; HPMC K15M was used to prepare the floating tablets to retard the drug release for 12h in stomach. Na-carboxymethyl cellulose (NaCMC) or carbopol 934P was added to alter the drug release profile or the dimensional stability of the formulation. Dicalcium phosphate (DCP) was used as filler. Formulations were evaluated for floating lag time, duration of floating, dimensional stability, drug content and in vitro drug release profile. The formulations were found to have floating lag time less than 1min. It was found that the dimensional stability of the formulations increase with increasing concentration of the swelling agent. The release mechanism of propranolol hydrochloride from floating tablets was evaluated on the basis of Peppas and Higuchi model. The ‘n’ value of the formulations ranged from 0.5201 to 0.7367 (0.5<n<1.0) which indicated anomalous (non-Fickian) transport mechanism. Formulation containing 27.5% HPMC K15M, 29% DCP, 3.75% citric acid and 18.75% sodium bicarbonate seemed most desirable. FTIR, DSC and XRPD studies indicated the absence of any significant chemical interaction within dug and excipients. Stability study of optimized formulation revealed no significant change and found to be stable.
机译:以柠檬酸和碳酸氢钠为泡腾剂,通过直接压片法研制了盐酸普萘洛尔肠胃片。羟丙基甲基纤维素; HPMC K15M用于制备漂浮片剂,以延迟药物在胃中的释放12小时。加入羧甲基纤维素钠(NaCMC)或carbopol 934P,以改变药物释放曲线或制剂的尺寸稳定性。磷酸氢钙(DCP)用作填充剂。评价制剂的漂浮滞后时间,漂浮持续时间,尺寸稳定性,药物含量和体外药物释放曲线。发现该制剂具有小于1分钟的浮动滞后时间。发现制剂的尺寸稳定性随溶胀剂浓度的增加而增加。根据Peppas和Higuchi模型评估了盐酸普萘洛尔从漂浮片中的释放机理。制剂的“ n”值介于0.5201至0.7367(0.5

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号